Search results for:
cancer
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy
Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "Receiving ODD for 225Ac-satoreotide is a recognition of its potential as a treatment option for patients with SCLC and an important regulatory milestone for Ariceum. The FDA's ODD will support our objective to accelerate the development of 225Ac-satoreotide through human trials to provide a potentially life-saving therapy to patients with limited alternatives."
From Standardized to Specialized: Revolutionizing Lung Cancer Care | By Ofer Sharon, MD, CEO of OncoHost
The future of lung cancer care lies in placing each patient’s unique biology at the center of every clinical decision. Through collaboration, innovation, and an unwavering commitment to advancing science, we can move closer to a world where every lung cancer patient benefits from a truly personalized treatment plan.
Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer
Hugh Salter, Chief Scientific Officer at Anocca, elaborated, "KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.”
Immorta Bio Reports | SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy
SenoVax has previously been demonstrated to reduce lung cancer growth1, which was the subject of the Company's IND #307452. It has also been shown to accelerate recovery of blood cell production after chemotherapy notes Immorta Bio.
Bracco Imaging S.A. and Arrayus Technologies Announce Agreement to Enhance Drug Delivery for Pancreatic Cancer Treatment Using Focused Ultrasound and Microbubble Technology
Under the terms of the agreement, Bracco Imaging will supply Arrayus with microbubbles for use in the development and commercialization of its focused ultrasound platform for pancreatic cancer.
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
"The approval from the MIEC, coming closely on the heels of our two ethics committee approvals in Australia, to conduct this early feasibility study, is another important step in our plan to evaluate use of the Hemopurifier as a treatment option in multiple tumor types, where cancer associated exosomes may promote immune suppression and metastasis," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical.
Sheba Medical Center to Utilize Sequentify’s InfiniSeq Panel in Study to Detect Clonal Hematopoiesis in Cancer Patients
Sequentify's InfiniSeq technology reduces sample preparation time to just 3.15 hours, from DNA extraction to sequencing, using a single-tube reaction. It supports full automation and significantly reduces costs. The patent-pending InfiniSeq technology is compatible with most sequencing machines and seamlessly integrates into any lab workflow.
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
“The Decipher Prostate test’s ability to help guide treatment for patients with localized prostate cancer is already proven in dozens of peer-reviewed publications and is the only molecular test to achieve ‘Level 1B’ evidence status in the most recent NCCN® Guidelines* for prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These new phase 3 data from the STAMPEDE trial now further prove the performance and utility of our test in patients with metastatic prostate cancer. We believe our test can have a tremendous positive impact on care for these patients.”
AI Can Detect Lung Nodules that Could Lead to Lung Cancer Nearly 3 Years Before Symptoms & Actual Diagnosis | Study finds
The study conducted at the Phrapokklao Hospital’s Cancer Centre of Excellence in Bangkok, Thailand was led by Dr Passakorn Wanchaijiraboon, Medical Oncologist and Deputy Director using the Qure.ai chest X-ray AI solution qXR.
Abhisek Swaika, MD to Lead Northwell Cancer Institute at Rego Park
“Dr. Abhisek Swaika is deeply committed to ensuring the delivery of the highest quality, state-of-the art cancer care,” said Richard Carvajal, MD, deputy physician-in-chief and director of medical oncology at Northwell Health Cancer Institute. “His leadership and experience will continue to drive our mission to care for the diverse patient population we have the privilege to see at our cancer center in Queens.”
FDA Approves Illumina Cancer Biomarker Test with 2 Companion Diagnostics to Rapidly Match Patients to Targeted Therapies
"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
"This analytical validation study strongly complements EsoGuard's extensive peer-reviewed, published clinical validity and clinical utility evidence base," said Suman Verma, M.D., PhD, Chief Scientific Officer at Lucid Diagnostics. "The results demonstrate very robust analytical performance of the EsoGuard assay performed in our CLIA-certified, CAP-accredited, NY State-approved commercial laboratory."